Releases › HCPCS Level II April 2025
HCPCS Level II April 2025
Effective 2025-04-01 to 2025-06-30. 8,725 codes in the release.
83added
22revised
37removed
Codes added 83
| Code | Description |
|---|---|
| A2030 | Miro3d fibers, per milligram |
| A2031 | Mirodry wound matrix, per square centimeter |
| A2032 | Myriad matrix, per square centimeter |
| A2033 | Myriad morcells, 4 milligrams |
| A2034 | Foundation drs solo, per square centimeter |
| A2035 | Corplex p or theracor p or allacor p, per milligram |
| A6515 | Gradient compression wrap with adjustable straps, full leg, each, custom |
| A6516 | Gradient compression wrap with adjustable straps, foot, each, custom |
| A6517 | Gradient compression wrap with adjustable straps, below knee, each, custom |
| A6518 | Gradient compression wrap with adjustable straps, arm, each, custom |
| A6519 | Gradient compression garment, not otherwise specified, for nighttime use, each |
| A6611 | Gradient compression wrap with adjustable straps, above knee, each, custom |
| A9154 | Artificial saliva, 1 ml |
| A9611 | Flurpiridaz f 18, diagnostic, 1 millicurie |
| C8004 | Simulation angiogram with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the angiogram, for subsequent therapeutic radioembolization of tumors |
| C8005 | Bronchoscopy, rigid or flexible, non-thermal transbronchial ablation of lesion(s) by pulsed electric field (pef) energy, including fluoroscopic and/or ultrasound guidance, when performed, with computed tomography acquisition(s) and 3d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) of all mediastinal and/or hilar lymph node stations or structures, and therapeutic intervention(s) |
| C9300 | Injection, indigotindisulfonate sodium, 1 mg |
| C9301 | Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
| C9302 | Injection, zanidatamab-hrii, 2 mg |
| C9303 | Injection, zolbetuximab-clzb, 1 mg |
| C9304 | Injection, marstacimab-hncq, 0.5 mg |
| E0201 | Penile contracture device, manual, greater than 3 lbs traction force |
| E1022 | Wheelchair transportation securement system, any type includes all components and accessories |
| E1023 | Wheelchair transit securement system, includes all components and accessories |
| E1032 | Wheelchair accessory, manual swingaway, retractable or removable mounting hardware used with joystick or other drive control interface |
| E1033 | Wheelchair accessory, manual swingaway, retractable or removable mounting hardware for headrest, cushioned, any type |
| E1034 | Wheelchair accessory, manual swingaway, retractable or removable mounting hardware for lateral trunk or hip support, any type |
| E1832 | Static progressive stretch finger device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories |
| G0183 | Quantitative software measurements of cardiac volume, cardiac chambers volumes and left ventricular wall mass derived from ct scan(s) data of the chest/heart (with or without contrast) |
| G0566 | 3d radiodensity-value bone imaging, algorithm derived, from previous magnetic resonance examination of the same anatomy |
| G0567 | Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe technique |
| J0281 | Injection, aminocaproic acid, 1 gram |
| J1072 | Injection, testosterone cypionate (azmiro), 1 mg |
| J1271 | Injection, doxycycline hyclate, 1 mg |
| J1299 | Injection, eculizumab, 2 mg |
| J1308 | Injection, famotidine, 0.25 mg |
| J1808 | Injection, folic acid, 0.1 mg |
| J1938 | Injection, furosemide, 1 mg |
| J2351 | Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq |
| J2428 | Injection, paliperidone palmitate extended release (erzofri), 1 mg |
| J2804 | Injection, rifampin, 1 mg |
| J2865 | Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg |
| J7521 | Tacrolimus, granules, oral suspension, 0.1 mg |
| J9024 | Injection, atezolizumab, 5 mg and hyaluronidase-tqjs |
| J9038 | Injection, axatilimab-csfr, 0.1 mg |
| J9054 | Injection, bortezomib (boruzu), 0.1 mg |
| J9161 | Injection, denileukin diftitox-cxdl, 1 mcg |
| L0720 | Cervical-thoracic-lumbar-sacral-orthoses (ctlso), anterior-posterior-lateral control, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
| L1933 | Ankle foot orthosis, rigid anterior tibial section, total carbon fiber or equal material, prefabricated, off-the-shelf |
| L1952 | Ankle foot orthosis, spiral, (institute of rehabilitative medicine type), plastic or other material, prefabricated, off-the-shelf |
| L5827 | Endoskeletal knee-shin system, single axis, electromechanical swing and stance phase control, with or without shock absorption and stance extension damping |
| L6028 | Partial hand including fingers, flexible or non-flexible interface, endoskeletal system, molded to patient model, for use without external power, not including inserts described by l6692 |
| L6029 | Upper extremity addition, test socket/interface, partial hand including fingers |
| L6030 | Upper extremity addition, external frame, partial hand including fingers |
| L6031 | Replacement socket/interface, partial hand including fingers, molded to patient model, for use with or without external power |
| L6032 | Addition to upper extremity prosthesis, partial hand including fingers, ultralight material (titanium, carbon fiber or equal) |
| L6033 | Addition to upper extremity prosthesis, partial hand including fingers, acrylic material |
| L6037 | Immediate post-surgical or early fitting, application of initial rigid dressing, including fitting alignment and suspension of components, and one cast change, partial hand including fingers |
| L6700 | Upper extremity addition, external powered feature, myoelectronic control module, additional emg inputs, pattern-recognition decoding intent movement |
| L7406 | Addition to upper extremity, user adjustable, mechanical, residual limb volume management system |
| Q2057 | Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose |
| Q4354 | Palingen dual-layer membrane, per square centimeter |
| Q4355 | Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter |
| Q4356 | Abiomend membrane and abiomend hydromembrane, per square centimeter |
| Q4357 | Xwrap plus, per square centimeter |
| Q4358 | Xwrap dual, per square centimeter |
| Q4359 | Choriply, per square centimeter |
| Q4360 | Amchoplast fd, per square centimeter |
| Q4361 | Epixpress, per square centimeter |
| Q4362 | Cygnus disk, per square centimeter |
| Q4363 | Amnio burgeon membrane and hydromembrane, per square centimeter |
| Q4364 | Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter |
| Q4365 | Amnio burgeon dual-layer membrane, per square centimeter |
| Q4366 | Dual layer amnio burgeon x-membrane, per square centimeter |
| Q4367 | Amniocore sl, per square centimeter |
| Q5147 | Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram |
| Q5149 | Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg |
| Q5150 | Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg |
| Q5151 | Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg |
| Q5152 | Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg |
| Q9999 | Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg |
| S4024 | Air polymer-type a intrauterine foam, per study dose |
Descriptions revised 22
| Code | Was, and is now |
|---|---|
| A4453 | |
| A4459 | |
| A6549 | |
| A6583 | |
| A6585 | |
| A6586 | |
| A6587 | |
| A6588 | |
| C1739 | |
| C9793 | |
| E1028 | |
| E1801 | |
| E1811 | |
| E1816 | |
| E1818 | |
| E1841 | |
| J9073 | |
| L1932 | |
| L1951 | |
| L1971 | |
| L6692 | |
| L6698 |
Terminated 37
| Code | Description |
|---|---|
| A9155 | Artificial saliva, 30 ml |
| G0564 | Creation of subcutaneous pocket with insertion of 365 day implantable interstitial glucose sensor, including system activation and patient training |
| G0565 | Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 365 day implantable sensor, including system activation |
| J1094 | Injection, dexamethasone acetate, 1 mg |
| J1300 | Injection, eculizumab, 10 mg |
| J1810 | Injection, droperidol and fentanyl citrate, up to 2 ml ampule |
| J1890 | Injection, cephalothin sodium, up to 1 gram |
| J1940 | Injection, furosemide, up to 20 mg |
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg |
| J9247 | Injection, melphalan flufenamide, 1mg |
| L8010 | Breast prosthesis, mastectomy sleeve |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
| M0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
| M0223 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
| M0241 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
| M0246 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg |
| Q0222 | Injection, bebtelovimab, 175 mg |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg |
| Q0247 | Injection, sotrovimab, 500 mg |
| Q4231 | Corplex p, per cc |
| Q5139 | Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg |
| S0017 | Injection, aminocaproic acid, 5 grams |
| S0028 | Injection, famotidine, 20 mg |
| S0032 | Injection, nafcillin sodium, 2 grams |
| S0039 | Injection, sulfamethoxazole and trimethoprim, 10 ml |
| S4988 | Penile contracture device, manual, greater than 3 lbs traction force |